

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

**INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED 30 JUNE 2026**

The board of directors (the “**Board**”) of Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”) is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (the “**Group**”) for the six months ended 30 June 2026. The results have been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Accounting Standards of the People’s Republic of China (the “**PRC**” or “**China**”).

* For identification purposes only

CONSOLIDATED BALANCE SHEET OF THE GROUP

Item	Note	As at 30 June 2026 RMB	As at 31 December 2025 RMB
Current assets:			
Monetary funds		1,380,852,986.07	1,409,120,983.52
Held-for-trading financial assets		745,064,308.22	811,246,684.93
Financial assets at fair value through profit or loss		—	—
Derivative financial assets		—	—
Notes receivable		2,581,984.85	4,253,186.08
Accounts receivable	2	253,086,616.89	225,456,558.88
Prepayment		4,232,768.38	4,851,870.27
Other receivables		2,292,983.09	222,608.48
Including: Interest receivable		—	—
Dividends receivable		—	—
Inventories		527,532,378.70	535,925,459.39
Contract assets		—	—
Assets held-for-sale		—	—
Non-current assets due within one year		—	—
Other current assets		29,138,268.62	20,422,698.85
Total current assets		2,944,782,294.82	3,011,500,050.40
Non-current assets:			
Debt investments		—	—
Available-for-sale financial assets		—	—
Other debt investments		—	—
Held-to-maturity investments		—	—
Long-term receivables		—	—
Long-term equity investments		—	—
Other investments in equity instruments		—	—
Other non-current financial assets		—	—
Investment property		—	—
Fixed assets		345,758,906.51	354,149,308.67
Construction in progress		130,696,918.06	129,329,592.01
Productive biological assets		—	—
Oil & gas assets		—	—
Right-of-use assets		3,849,284.26	3,840,500.22
Intangible assets		114,958,897.77	119,787,805.08
Development expenditures		—	—
Goodwill		—	—
Long-term prepayments		—	—
Deferred income tax assets		29,409,006.47	30,336,378.81
Other non-current assets		21,904,673.73	12,191,225.94
Total non-current assets		646,577,686.80	649,634,810.73
Total assets		3,591,359,981.62	3,661,134,861.13

Item	Note	As at 30 June 2026 RMB	As at 31 December 2025 RMB
Current liabilities:			
Short-term borrowings		—	—
Held-for-trading financial liabilities		—	—
Financial liabilities at fair value through profit or loss		—	—
Derivative financial liabilities		—	—
Notes payable		—	—
Accounts payable	3	117,724,327.54	160,772,940.21
Advances received		—	—
Contract liabilities		74,626,090.87	82,166,218.34
Employee remuneration payable		46,961,711.58	68,607,725.23
Taxes payable		12,048,571.37	26,060,319.15
Other payables		146,798,847.65	181,961,490.77
Including: Interests payable		—	—
Dividends payable		43,062,742.11	80,260,246.29
Liabilities held-for-sale		—	—
Non-current liabilities due within one year		2,563,278.73	2,677,095.45
Other current liabilities		49,149,448.02	56,357,165.80
Total current liabilities		449,872,275.76	578,602,954.95
Non-current liabilities:			
Long-term borrowings		—	—
Bonds payable		—	—
Including: Preferred shares		—	—
Perpetual bonds		—	—
Lease liabilities		497,060.35	598,047.04
Long-term payables		—	—
Long-term employee remuneration payable		—	—
Estimated liabilities		—	—
Deferred gains		80,354,183.05	82,494,938.18
Deferred income tax liabilities		11,033,796.14	12,446,459.51
Other non-current liabilities		—	—
Total non-current liabilities		91,885,039.54	95,539,444.73
Total liabilities		541,757,315.30	674,142,399.68

Item	Note	As at 30 June 2026 RMB	As at 31 December 2025 RMB
Shareholders' equity:			
Share capital	4	383,568,500.00	383,568,500.00
Other equity instruments		—	—
Including: Preferred shares		—	—
Perpetual bonds		—	—
Capital reserve	5	1,044,799,419.83	1,044,799,419.83
Less: Treasury shares		20,008,021.82	20,008,021.82
Other comprehensive income		—	—
Specific reserve		—	—
Surplus reserve	6	225,066,727.32	225,066,727.32
Undistributed profits	7	<u>1,414,669,481.53</u>	<u>1,352,041,210.82</u>
Total interests attributable to shareholders of the parent company		3,048,096,106.86	2,985,467,836.15
Minority interests		<u>1,506,559.46</u>	<u>1,524,625.30</u>
Total shareholders' equity		<u>3,049,602,666.32</u>	<u>2,986,992,461.45</u>
Total liabilities and shareholders' equity		<u>3,591,359,981.62</u>	<u>3,661,134,861.13</u>
Net current assets		<u>2,494,910,019.06</u>	<u>2,432,897,095.45</u>
Total assets less current liabilities		<u>3,141,487,705.86</u>	<u>3,082,531,906.18</u>

CONSOLIDATED INCOME STATEMENT OF THE GROUP

Item	Notes	Six months ended 30 June	
		2026 RMB	2025 RMB
I. Revenue	8	417,104,217.14	487,596,405.66
Less: Operating costs	8	147,785,747.32	160,472,617.89
Taxes and surcharge		4,246,542.01	4,531,943.83
Selling expenses		65,783,090.88	96,267,759.62
Administrative expenses		19,561,228.97	28,394,457.44
Research and development expenses		47,226,656.71	50,854,271.53
Financial expenses		1,404,286.26	(6,743,274.50)
Including: Interest expenses		76,746.69	12,292.70
Interest proceeds		7,282,885.42	7,674,348.71
Add: Other gains		4,390,159.68	5,307,719.73
Investment income/(losses)		2,818,027.41	3,217,026.86
Including: Investment income from associates and joint ventures		—	—
Gains/(losses) from derecognition of financial assets measured at amortized cost		—	—
Gain/(losses) on net exposure hedges		—	—
Gain/(losses) from changes of fair value		3,648,527.39	4,296,252.04
Impairment loss of credit		(820,156.72)	(12,418,491.12)
Impairment loss of assets		(6,043,562.98)	(26,911,765.98)
Gains/(losses) on disposal of assets		—	3,848.03
II. Operating profit/(losses)		135,089,659.77	127,313,219.41
Add: Non-operating income		160,577.65	0.84
Less: Non-operating expenses		1,792,993.29	700.00
III. Total profit/(losses)		133,457,244.13	127,312,520.25
Less: Income tax expenses	9	13,518,291.91	12,831,365.21

Item	Notes	Six months ended 30 June	
		2026 RMB	2025 RMB
IV. Net profit/(losses)		119,938,952.22	114,481,155.04
(I) Categorized by continuity of operations:			
1. Net profit attributable to continuing operations		119,938,952.22	114,481,155.04
2. Net profit attributable to ceased operations		<u>—</u>	<u>—</u>
(II) Categorized by ownership:			
1. Net profit attributable to the shareholders of the parent company		119,957,018.06	114,469,490.87
2. Minority profit or loss		(18,065.84)	11,664.17
V. Net other comprehensive income after tax			
Net other comprehensive income after tax attributable to the shareholders of the parent company		<u>—</u>	<u>—</u>
Net other comprehensive income after tax attributable to minority shareholders		<u>—</u>	<u>—</u>
VI. Total comprehensive income		119,938,952.22	114,481,155.04
Total comprehensive income attributable to the shareholders of the parent company		119,957,018.06	114,469,490.87
Total comprehensive income attributable to minority shareholders		(18,065.84)	11,664.17
VII. Earnings per share			
(I) Basic earnings per share	10	0.31	0.30
(II) Diluted earnings per share	10	0.31	0.30

NOTES:

1 GENERAL

Beijing Chunlizhengda Medical Instruments Co., Ltd.* (hereinafter referred to as the “**Company**”) was established as a limited liability company in the People’s Republic of China (the “**PRC**” or “**China**”) on 12 February 1998.

The H shares of the Company have been listed and traded on the Hong Kong Stock Exchange since 11 March 2015 under the stock short name “Chunli Medical” and stock code 01858.HK; and the A shares of the Company have been listed and traded on the Science and Technology Innovation Board of the Shanghai Stock Exchange since 30 December 2021 under the stock short name “Chunli Medical” and stock code 688236.SH.

The Company operates in the medical device industry, and is mainly engaged in the research and development, production and sales of medical device products for joints, spine and sports medicine.

Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Company’s accounting policies which conformed to the Accounting Standards for Business Enterprises in the PRC (the “**ASBE**”) issued by the Ministry of Finance of the PRC (the “**MOF**”), the related specific standards, the Accounting Standards for Business Enterprises Application Guidance, the PRC Accounting Standards Bulletins and other relevant regulations (hereinafter referred to as the “China Accounting Standards for Business Enterprises”, the “**CASBE**”).

In preparing the financial statements of the Company as of 30 June 2026, the Group has adopted all of the new and revised CASBE issued by the MOF that are effective as of 30 June 2026.

2 ACCOUNTS RECEIVABLE

Categories of accounts receivable:

Item		Individually significant and for which provision is individually assessed	Provision made for bad debts by portfolios	Credit risk group	Sub-total	Not individually significant but for which provision is individually assessed	Total
As at 31 December 2025							
Carrying amount	Amount (RMB)	—	289,530,327.48	289,530,327.48	289,530,327.48	—	289,530,327.48
	Percentage (%)	—	100%	100%	100%	—	100%
Provision	Amount (RMB)	—	64,073,768.60	64,073,768.60	64,073,768.60	—	64,073,768.60
	Percentage (%)	—	22.13	22.13	22.13	—	22.13
Net amount		—	225,456,558.88	225,456,558.88	225,456,558.88	—	225,456,558.88
As at 30 June 2026							
Carrying amount	Amount (RMB)	—	317,974,289.59	317,974,289.59	317,974,289.59	—	317,974,289.59
	Percentage (%)	—	100%	100%	100%	—	100%
Provision	Amount (RMB)	—	64,887,672.70	64,887,672.70	64,887,672.70	—	64,887,672.70
	Percentage (%)	—	20.41	20.41	20.41	—	20.41
Net amount		—	253,086,616.89	253,086,616.89	253,086,616.89	—	253,086,616.89

Credit risk characteristics group:

Aging	As at 30 June 2026			As at 31 December 2025		
	Carrying amount		Provision amount	Carrying amount		Provision amount
	RMB	Percentage %	RMB	RMB	Percentage %	RMB
Within 1 year	235,335,220.25	74.01	11,766,761.01	204,620,812.90	70.67	10,231,040.64
1 to 2 years	28,458,117.85	8.95	4,268,717.68	23,082,781.57	7.97	3,462,417.23
2 to 3 years	10,657,514.97	3.35	5,328,757.49	22,892,844.58	7.91	11,446,422.30
More than 3 years	43,523,436.52	13.69	43,523,436.52	38,933,888.43	13.45	38,933,888.43
Total	<u>317,974,289.59</u>	<u>100.00</u>	<u>64,887,672.70</u>	<u>289,530,327.48</u>	<u>100.00</u>	<u>64,073,768.60</u>

Note: The aging analysis of accounts receivable is based on the month in which the amount actually occurs. The amount which occurs first has priority in settlement.

3 ACCOUNTS PAYABLE

Item	As at 30 June 2026 RMB	As at 31 December 2025 RMB
Acquired materials and others	100,950,004.00	131,660,213.78
Acquired machines equipment and engineering	<u>16,774,323.54</u>	<u>29,112,726.43</u>
Total	<u>117,724,327.54</u>	<u>160,772,940.21</u>

Aging analysis of accounts payable is as follows:

Item	As at 30 June 2026 RMB	As at 31 December 2025 RMB
Within 1 year (inclusive)	88,580,652.82	130,243,026.01
More than 1 year	<u>29,143,674.72</u>	<u>30,529,914.20</u>
Total	<u>117,724,327.54</u>	<u>160,772,940.21</u>

Note: The aging analysis of accounts payable is based on the month in which the amount actually occurs. The amount which occurs first has priority in settlement.

4 SHARE CAPITAL

	Six months ended 30 June			
	2026		2025	
	<i>Number of shares</i>	<i>RMB</i>	<i>Number of shares</i>	<i>RMB</i>
Overseas-listed foreign shares (H Shares) in the ordinary shares with a nominal value of RMB1.00 each	95,140,500	95,140,500	95,140,500	95,140,500
A Shares	288,428,000	288,428,000	288,428,000	288,428,000
	383,568,500	383,568,500	383,568,500	383,568,500

5 CAPITAL RESERVE

Item	As at 30 June 2026 <i>RMB</i>	As at 31 December 2025 <i>RMB</i>
Capital premium	1,042,999,419.83	1,042,999,419.83
Other capital reserve	1,800,000.00	1,800,000.00
Total	1,044,799,419.83	1,044,799,419.83

6 SURPLUS RESERVE

Item	As at 30 June 2026 <i>RMB</i>	As at 31 December 2025 <i>RMB</i>
Statutory surplus reserve	225,066,727.32	225,066,727.32

As stipulated by the relevant laws and regulations for enterprises in the PRC, each of the entities comprising the Group is required to maintain a statutory reserve fund which is non-distributable. The appropriations to such reserve fund are made out of net profit after taxation of the statutory financial statements of the relevant PRC companies. The statutory surplus reserve can be used to make up prior year/period losses, if any, and can be applied in conversion into capital by means of capitalization issue.

7 RETAINED EARNINGS

Item	As at 30 June 2026 RMB	As at 31 December 2025 RMB
Closing balances of the preceding year	<u>1,352,041,210.82</u>	<u>1,208,437,565.70</u>
Opening balances of the current year	1,352,041,210.82	1,208,437,565.70
Add: Net profit attributable to the owners of the parent company for the period	119,957,018.06	272,542,347.59
Less: Transfer to statutory reserve fund	—	29,951,065.38
Declaration of dividend	57,328,747.35	98,987,637.09
Dividend of ordinary shares transferred to share capital	—	—
Closing balances of the current year	<u>1,414,669,481.53</u>	<u>1,352,041,210.82</u>

8 REVENUE AND COST OF SALES

Item	Six months ended 30 June 2026 RMB	2025 RMB
Revenue from principal operation	416,865,201.78	487,043,907.76
Revenue from other operations	<u>239,015.36</u>	<u>552,497.90</u>
Cost of sales	<u>147,785,747.32</u>	<u>160,472,617.89</u>

Revenue and cost of sales (classified by products)

Item	Six months ended 30 June 2026 RMB	2025 RMB
Revenue		
Revenue from principal operation:		
— Medical Surgical Implants	<u>416,865,201.78</u>	<u>487,043,907.76</u>
Cost of sales		
Cost of sales for principal operation:		
— Medical Surgical Implants	<u>147,782,840.62</u>	<u>160,228,803.61</u>

9 INCOME TAX EXPENSES

Item	Six months ended 30 June	
	2026	2025
	RMB	RMB
Current income tax calculated in accordance with relevant tax laws and regulations	14,003,582.94	16,116,030.44
Deferred income tax	(485,291.03)	(3,284,665.23)
Total	<u>13,518,291.91</u>	<u>12,831,365.21</u>

Applicable tax rate

Information of corporate income tax rates for different taxable entities as of 30 June 2026:

Name of Taxable Entity	Standard Corporate Income Tax Rate	Applicable Corporate Income Tax Rate
Beijing Chunlizhengda Medical Instruments Co., Ltd.* (北京市春立正達醫療器械股份有限公司)	25%	15%
Beijing Zhao Yi Te Medical Devices Co., Ltd.* (北京兆億特醫療器械有限公司)	25%	Income tax rates for small and micro enterprises
Hebei Chunli Hangnuo New Materials Technology Co., Ltd.* (河北春立航諾新材料科技有限公司)	25%	15%
Beijing Shiyue Changsheng Medical Devices Co., Ltd.* (北京實躍長盛醫療器械有限公司)	25%	Income tax rates for small and micro enterprises
Xingtai Langtai Benyuan Medical Devices Co., Ltd.* (邢台市琅泰本元醫療器械有限公司)	25%	Income tax rates for small and micro enterprises
Langtai Meikang Medical Devices Co., Ltd.* (琅泰美康醫療器械有限公司)	25%	Income tax rates for small and micro enterprises
Beijing Lechi Inspection Technology Co., Ltd.* (北京樂馳檢測技術有限公司)	25%	Income tax rates for small and micro enterprises
Surgimaster Surgical Co., Ltd.* (舒捷醫療科技(蘇州)有限公司)	25%	Income tax rates for small and micro enterprises

Reconciliation of current income tax expenses to the accounting profit is as follows:

Item	Six months ended 30 June	
	2026 RMB	2025 RMB
Profit before tax	133,457,244.13	127,312,520.25
Income tax expenses based on statutory/applicable tax rate	20,018,586.62	19,096,878.04
Effect of different tax rate applicable to subsidiaries	(311,247.85)	161,631.96
Effect of prior income tax reconciliation	41,495.47	—
Effect of non-deductible costs, expenses and losses	720,718.00	750,751.64
Effect of using the deductible temporary differences or deductible losses of previously unrecognized deferred income tax assets	(103,467.01)	—
Effects of additional deduction of research and development costs and others	(6,851,829.77)	(7,313,286.54)
Effect of deductible temporary differences or deductible losses of unrecognized deferred income tax assets in the current period	32,445.92	168,024.34
Additional deduction of the wages for employment of disabled persons	(28,409.47)	(32,634.23)
Income tax expenses	13,518,291.91	12,831,365.21

10 EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT COMPANY

The calculation of the basic earnings per share amount is based on the profit for the year attributable to ordinary equity holders of the parent company, and the weighted average number of ordinary shares of 383,568,500 (2025: 383,568,500) shares in issue.

As of 30 June 2026, the Group had no potentially dilutive ordinary shares in issue.

Profit

	Six months ended 30 June	
	2026 (RMB)	2025 (RMB)
Profits attributable to ordinary equity holders of the parent company for the purpose of calculating basic and diluted earnings per share	119,957,018.06	114,469,490.87

Shares

	Six months ended 30 June	
	2026	2025
Weighted average number of ordinary shares in issue for the purpose of calculating basic and diluted earnings per share	383,568,500	383,568,500

11 SEGMENT INFORMATION

The Group is mainly engaged in the manufacture and trading of surgical implants, instruments and related products. Based on the Group's internal organisational structure, management requirements and internal reporting policies, the operation of the Company constitutes one single reportable segment, i.e. manufacturing and trading of surgical implants, instruments and related products, which is under the provisions on segment information in business statements of the "ASBE No. 35 – Segment Reporting" and "Interpretation No. 3 on ASBE" and accordingly, no separate segment information is prepared.

MANAGEMENT DISCUSSION AND ANALYSIS

The main products of the Company are orthopedic medical devices^(note 1) and tissue repair products, including spine, trauma, joint, sports medicine and bone repair material implants, surgical instrumentation products, as well as platelet-rich plasma (PRP) preparation kits and closed wound negative pressure drainage kits. According to the Guidelines for the Industry Classification of Listed Companies (2024 Revision) issued by the CSRC, the industry in which the Company operates is “special equipment manufacturing industry” (classification code: C35). According to the Classification of Strategic Emerging Industries (2018), the Company falls under “4.2.2 Manufacture of Interventional Biomedical Materials and Equipment” in “4.2 Biomedical Engineering Industry”. According to “Industrial Classification for National Economic Activities” (《國民經濟行業分類》) (GB/T4754–2017), the industry in which the Company operates is “implantable (interventional) medical devices manufacturing” under “other medical equipment and instruments manufacturing” (classification code: C3589) in “medical instruments, equipment and instruments manufacturing” (classification code: C358).

The topic of health has become a global hotspot, with the economic development, the increasing degree of social ageing, coupled with the gradual enhancement of awareness for healthcare. People’s increasing demand for high-quality medical treatment has in turn promoted the prosperous development of the global medical device market. Under the context of the healthcare reform in China, medical devices have been included in medical care insurance coverage, which has increased the market demand and patient’s acceptance for orthopedic implants^(note 2). In addition, various favorable factors such as the aging population, the continuous growth in healthcare expenditure and the improvements in public healthcare infrastructure have promoted the growth of the orthopedic medical industry in the PRC.

In 2024, the successive implementation of policy of centralized procurement of high-value orthopedic consumables in China had caused certain impact on the development of the orthopedic industry, and the Company continued to seek innovation and research and development, firmly insisting on the orthopedic business and continuously expanded its diversified product lines.

Note 1: Orthopedic medical devices refer to medical devices that are used for orthopedic disease treatment and recovery, mainly including orthopedic medical implant instruments and orthopedic operation instruments.

Note 2: Orthopedic implants refer to medical device products that are used for replacing or providing adjuvant treatment for injured bones and skeletons and implanted into human bodies, including joint implants (such as knee joints, hip joints, shoulder joints and elbow joints), spine implants (such as lumbar cage), sports medicine implants (such as suture anchors, looped titanium plates and door-shaped anchors) and trauma implants (such as calcaneal plates and bone pegs), excluding dental fillings.

On 3 January 2025, the General Office of the State Council issued the “Opinions on Comprehensively Deepening the Reform of Drug and Medical Device Regulation to Promote High Quality Development of the Pharmaceutical Industry”, which clearly stated that the government shall increase support for the research and development (“**R&D**”) and innovation of pharmaceuticals and medical devices and enhance the quality and efficiency of the review and approval of pharmaceuticals and medical devices. China’s intention of increasing support for the innovation of medical devices and accelerating their review and approval is beneficial for the medical device industry. As the Manufacturing Champion Enterprise of Artificial Joint Prosthesis (Single-item) recognized by the Ministry of Industry and Information Technology (MIIT), the Company actively upholds national policies, increasing its R&D efforts in innovative medical devices, and thereby contributing to the national initiative of building a pharmaceutical industry with stronger innovation creativity and global competitiveness.

During the reporting period, the Company conducted in-depth research and analysis on the national volume-based procurement policy. It actively implemented the policy to ensure a stable supply of selected products, regulate the procurement and usage practices of medical institutions, and facilitate the smooth implementation of the selected results for orthopedic-related centralized procurement.

In the field of artificial joints, in May 2024, the Renewal in Centralized Volume-based Procurement for Artificial Joints was opened for bidding in Tianjin and the selected result had been announced, among which, all the three product systems for hip joints as well as the total knee products of the Company had been successfully selected.

In the field of spinal products, in the centralized volume-based procurement of spinal consumables organized by the state in 2023, all eight product system categories submitted by the Company were successfully selected, and they are currently being implemented in various provinces.

In the field of sports medicine, the state-organized centralized banded procurement of IOL and sports medicine consumables was opened in Tianjin in November 2023, and all the sports medicine products of the Company won the bidding, which has increased the share of total demand. The Company is actively promoting the marketing network construction to further increase its market share.

Through the research and development of new materials, products, technologies and processes, the Company has continued to assess and invest in research and development projects. For instance, the Company has made corresponding arrangements for the research and development of new materials such as porous tantalum, magnesium alloy and PEEK, and enhanced the research and development of products for new pipelines including surgical robots, sports medicine, PRP and oral cavity. The strategic arrangements above are made to continue to improve the Company’s product lines and enhance its competitiveness in the market.

While the Company has made in-depth deployment in the field of orthopedic high-value consumables, it has also strengthened its expansion in orthopedic-related fields, actively searched for advanced technologies and excellent products, and enriched its product reserves to further increase its market share and realize long-term stable and sustainable development in the medical field.

Comprehensive medical device registration certificates

According to the domestic joint products registration index (國產關節類產品註冊檢索) of the National Medical Products Administration (“NMPA”), the Company is one of the domestic enterprises that hold the most comprehensive medical device registration certificates for joint prosthesis products in the PRC in terms of the number and type of certificates.

In the field of artificial joints, the Company has obtained registration certificates for components of the hip joint prosthesis system, total knee joint prosthesis, bio-type unicondylar knee joint prosthesis, and the total knee replacement auxiliary measurement system. The launch of these new products further enriches the categories of joint product lines and will promote a further increase of the market share of the Company’s artificial joint products.

In the field of spinal products, the Company has obtained registration certificates for the thoracolumbar anterior pedicle screw-rod fixation system and the single-use annulus fibrosus suturing device. Obtaining the above-mentioned registration certificates for spinal products has enriched the spinal product line of the Company, further enhanced the Company’s market competitiveness in the spinal orthopedic industry.

In the field of sports medicine products, the Company has obtained registration certificates for products including the meniscus double-needle instrument, which further enriched its sports medicine product line, marking the further improvement of its deployment in the field of sports medicine, and the comprehensive sports medicine product line facilitated the selection of clinical use.

In the field of trauma, the Company has actively researched and developed the products in the field of trauma business. As of 30 June 2026, the launch of various products of the Company’s trauma product series had been approved, including bone plate, intramedullary nail, external fixation frame, metal bone needle, hollow bone screws, and titanium mesh plate system which further complemented the orthopedic business product line of the Company.

In the field of stomatologic products, the Company has obtained the registration certificates for machinable abutment posts and screws, stainless steel orthodontic wires and other products. This had further diversified the Company’s stomatologic product line and expanded its layout in the stomatologic product field. With the aim of building a comprehensive one-stop stomatologic ecosystem solution, the Company has planned comprehensive solutions in various stomatologic sub-sectors, namely orthodontics, implantology, repair and maxillofacial surgery.

In the field of PRP products, the Company has obtained marketing approval for the Platelet-Rich Plasma Preparation Kit and the Medical Centrifuge. The Platelet-Rich Plasma Preparation Kit is the first fully automated platelet-rich plasma preparation system in China. The Medical Centrifuge falls under the active medical device category, and the certification and successful launch of this product signified the Company’s further expansion in the PRP-product matrix.

In the field of rehabilitation robots, the Company has continued to deepen its technological presence by obtaining two medical device registration certificates for hip joint walking assistance devices and knee joint walking assistance devices. The product integrates multi-dimensional force sensing technology and adaptive gait algorithms to accurately identify the patient’s movement intention and output personalized assistive torque, achieving an intelligent upgrade from “passive fixed training” to “active intention following”. As such, the Company has formed a complete closed-loop solution in the field of orthopedics, encompassing “intraoperative robot-assisted precision replacement” and “postoperative intelligent assisted rehabilitation”, providing strong support for the standardized, digitalized, and precise development of lower limb rehabilitation therapy.

As of 30 June 2026, the Company held 237 medical device registration certificates and recordation certificates in the PRC, covering joint products, spinal products, sports medicine products, trauma, stomatologic products, PRP products and surgical robots. The various registration certificates further diversified the Company's product lines and expanded the Company's layout in the medical field to constantly meet the diversified market and clinical needs. This will strengthen the Company's comprehensive competitiveness and be conducive to further enhancing the Company's market expansion capability.

As for the international registration, as of 30 June 2026, the Company has obtained registration certificates from multiple countries. All three product series of the hip, knee and spine of the Company successfully passed the CE annual system audit and supervision audit. Meanwhile, the Company received the approval of FDA 510(K) in the US for its "Knee Prosthesis System". The certificates not only serve as proof of the satisfactory performance of the product and its compliance with product safety requirements, but also demonstrate the Company's technical superiority at an international level. Obtaining these certificates is a guarantee for our increasing international sales and a manifestation of our strong competitiveness in the international market.

Diversified product portfolio

As a leading listed company of implantable orthopedic medical devices in China, the Company has always focused on the research and development, production and sale of artificial joint products, spinal internal fixation products and sports medicine products, while actively expanding into the cutting-edge fields such as dentistry, PRP preparation system, and orthopedic surgical robots. Currently, the Company has successfully obtained the registration certificates for the world's first handheld "trinity" joint-replacement surgical robot for hip joints, knee joints and uni-condyle joints, achieving the breakthrough in intelligent surgical solutions; it has taken the lead in obtaining the domestic registration certificates for porous tantalum Class III medical devices with chemical vapor deposition (CVD) technology, breaking the long-term monopoly of foreign countries in the field of high-end biomaterials; it has also obtained the registration certificates for implant-related products, achieving the breakthrough in its dental layout.

Strong research and development capabilities

The Company is a National Manufacturing Champion Enterprise of Artificial Joint Prosthesis (Single-item), a Specialized and New "Little Giant" Enterprise, a National High-tech Enterprise and is certified by the National Enterprise Technology Center, maintaining a leading position in the domestic artificial joint industry and serving as an important force for the domestic replacement of high-end medical devices in China.

The Company has achieved extensive results in industry, academia and research. Over the past five years, we have secured approval for two key research and development projects of the Ministry of Science and Technology, four open-tender projects of MIIT, two projects under the National Postdoctoral Research Fund and one project under the National Natural Science Foundation. Through collaborating with universities, research institutes and medical institutions, taking into account the clinical needs of products and implementing procedures including mechanism research, prototype development and clinical validation, the Company has established a stable mechanism for developing new products, to ensure its products align with market demands.

During the reporting period, the research and development projects of the Company recognized by the government include:

- “Development of a high-wear-resistance unicondylar knee joint prosthesis” – a 2026 Beijing “Capital High-end Leading Talent Gathering and Training Programme” science and technology innovation leading talent project;
- “Development and evaluation of a novel paediatric tumour hemi-elbow joint prosthesis based on intelligent composite biological coatings and additive manufacturing technology” – a 2026 Beijing Natural Science Foundation project;
- “Development and application of patellofemoral joint prosthesis” – a project which won the first prize in the First Hebei Province Medical Science and Technology Achievement Transfer and Transformation Innovation Competition in 2026.

Apart from the above research and development projects, the Company was awarded as an enterprise leading an individual field of the manufacturing industry at the National Level by the MIIT in 2024. The Company is the first and currently the only enterprise leading an individual field of the manufacturing industry that focuses on the main business of artificial joint prosthesis. It shows full affirmation from MIIT for the Company’s persistent innovation-driven, excellence-driven and continuous pursuit of excellence in the field of artificial joints over the long term.

As of 30 June 2026, the Company had obtained 760 domestic intellectual properties, including 207 invention patents, 530 utility model patents, 7 design patents and 16 software copyrights. The abundant patent licenses manifest the Company’s innovation ability and core competitiveness. In the 23rd China Patent Award announced by China National Intellectual Property Administration, the “New Axis Knee Joint Prosthesis” of the Company was awarded the Outstanding Award of the China Patent Award. China Patent Award is the highest national accolade in the field of intellectual property, and getting the award demonstrates the level of patent technology and innovation of the Company. It is also a recognition of the Company’s patent market transformative value, patent protection and patent management.

Advanced joint prosthesis products

The Company is one of the earliest enterprises manufacturing advanced joint prosthesis products in the PRC.

The Company continuously innovated in research and development, with a number of products becoming the first in China, or filling the domestic gaps:

- In 2015, it obtained the medical device registration certificate of BIOLOX®*delta* fourth generation (the most widely used generation at present) ceramic joint prosthesis products, making the Company the first enterprise to acquire the all-ceramic certificate in mainland China, and also the first to gain the refurbished ceramics in the PRC;

- It is the first enterprise in China to have both flexible platform uni-condyle and fixed platform uni-condyle products;
- It is the first enterprise in China to have patellofemoral joint products;
- It is the first enterprise in China to have the Vitamin E high cross-linked polyethylene hip and knee products;
- It is the first enterprise in China to have inverted shoulder joint products;
- It is the first enterprise in China to possess the fully automatic PRP manufacturing system;
- It is the first enterprise in China to have titanium-zirconium hydrophilic implants;
- It is the first enterprise in China to have light-curing glass ionomer cement;
- It is the first enterprise in China to have one-piece ultra-narrow implants;
- It is the first and sole enterprise in China to have products with CVD technology such as porous tantalum metal femoral head reconstruction rods, tantalum metal filler blocks, hip joint prosthesis components, and porous tantalum metal interbody fusion devices, filling the domestic gaps.

In addition, the Company has also made arrangements for its joint robots and developed orthopedic surgical robots for hip replacement, total knee replacement, uni-condyle joint replacement and other product lines. Among them, the hip joint surgical robots are the first approved handheld orthopedic robots with autonomous sensing all over the world.

Extensive distribution and sales network

The Company has built an extensive distribution network covering all provinces, municipalities and autonomous regions in the PRC (excluding Hong Kong, Macau and Taiwan), and our sales network has covered numerous hospitals located in these regions through our distributors. Most of the products of the Company are sold in the PRC and some are exported to countries and regions in Asia, South America, Africa, Oceania and Europe under the brand name of “春立 Chunli” or through OEM.

FINANCIAL REVIEW

Revenue

The Company's revenue was approximately RMB417.10 million for the six months ended 30 June 2026, representing a decrease of 14.46% as compared to approximately RMB487.60 million for the same period of last year. This was mainly attributable to the pace of implementation of centralized procurement for orthopedic products and other periodic market factors both domestically and internationally, which resulted in a decline in revenue for the period.

The revenue of our major products compared with that of the previous year is as follows:

Product category	Six months ended 30 June		Growth over corresponding period
	2026 (RMB'000)	2025 (RMB'000)	
Medical device products	416,865	487,044	-14.41%
Other businesses	239	552	-56.70%
Total	417,104	487,596	-14.46%

Selling expenses

For the six months ended 30 June 2026, the Company's selling expenses were approximately RMB65.78 million, representing a decrease of 31.67% as compared to approximately RMB96.27 million for the same period of last year, which was mainly attributable to the optimization of marketing resource allocation and the improved efficiency of selling expenses.

Income tax expenses

For the six months ended 30 June 2026, the Company's income tax expenses were approximately RMB13.52 million, representing an increase of 5.35% from approximately RMB12.83 million for the same period of last year, which was mainly attributable to the increase in the profit of the Company.

Net profit

For the six months ended 30 June 2026, the Company achieved a net profit attributable to the shareholders of the parent company of approximately RMB119.96 million, representing an increase of 4.79% from approximately RMB114.47 million for the same period of last year. This was mainly attributable to the Company's continuous and stable supply of products under centralized procurement, optimization of its product and market structure, and strengthening of the competitiveness of its core businesses during the reporting period, which effectively contributed to the steady growth in the Company's profitability.

Liquidity and capital resources

The Company's monetary funds decreased from approximately RMB1,409.12 million as of 31 December 2025 to approximately RMB1,380.85 million as of 30 June 2026.

The Company's principal sources of liquidity are generated from our operations. The Board is of the opinion that the Company has sufficient resources to support its management and to meet its foreseeable capital expenditure demands.

Use of Proceeds from the Listing on the Science and Technology Innovation Board

Upon the approval of the listing committee of the Science and Technology Innovation Board of the Shanghai Stock Exchange and pursuant to the document for the approval of registration Zheng Jian Xu Ke (2021) No. 3702 (證件許可(2021) 3702號) issued by the China Securities Regulatory Commission, on 30 December 2021, the Company completed the A Share offering of 38,428,000 A Shares on the Science and Technology Innovation Board of the Shanghai Stock Exchange at an issue price of RMB29.81 per share, raising gross proceeds of RMB1,145,538,680.00 through the A Share offering. After deducting the issue expenses of RMB78,410,387.77, the actual net proceeds from the A Share offering amounted to RMB1,067,128,292.23. The net proceeds from the initial public offering of A Shares will continue to be used in accordance with the uses described in the Company's A Share offering prospectus dated 14 December 2021 and the Company's announcement dated 30 August 2023.

Use of Proceeds	Proportion	Amount available (RMB'000)	Balance of proceeds carried forward as at 1 January 2026 (RMB'000)	Net interest (expense)/income for the current period (RMB'000)	Net interest (expense)/income as of 30 June 2026 (RMB'000)	Balance of proceeds as of 30 June 2026 (RMB'000)	Amount temporarily used for cash management (Note) (RMB'000)	Amount of proceeds after deducting cash management (Note) (RMB'000)	The date on which the project is ready for its intended useable condition
Integrated construction project of orthopedic implant and ancillary materials (Build a production base and purchase relevant high-precision processing equipment to increase its product capacity and enrich its product structure)	43.11%	460,000.00	313,558.45	9,858.47	(156,300.02)	303,699.98	290,000.00	13,699.98	December 2026
Research and development centre construction project (Invest in R&D projects, focusing on the application of cutting-edge domestic and international technologies in actual products, improving existing products, and enhancing product responsiveness to market demand. In addition, a new R&D centre will be built, mainly focusing on new material research, product development, and the establishment of testing institutions and laboratories, etc.)	39.36%	420,000.00	239,135.10	21,843.99	(202,708.89)	217,291.11	185,000.00	32,291.11	December 2026
Marketing network construction project (Build a nationwide marketing system based on the Company's existing sales network to enhance the Company's market sales capabilities, customer service capabilities, and distributor management capabilities, etc.)	1.87%	20,000.00	12,829.26	3,647.66	(10,818.40)	9,181.60	-	9,181.60	December 2026
Replenishment of working capital	15.66%	167,128.29	69.35	(0.02)	(167,058.92)	69.37	=	69.37	N/A
	100%	1,067,128.29	565,592.16	35,350.11	(536,886.23)	530,242.06	475,000.00	55,242.06	

Note: According to relevant A-share laws and regulations, the Company may conduct cash management on temporarily idle proceeds. The Company confirms that the subscription of structured deposit products is only part of its fund management arrangements, with the aim of preserving principal and enhancing the return on temporarily idle funds. Such subscriptions do not constitute, and are not intended to constitute a use of the relevant proceeds for purposes other than the proposed uses previously disclosed by the Company. Upon the maturity, termination or redemption of the relevant structured deposit products, the relevant proceeds will be returned to the Company and continue to be used for their respective proposed uses as previously disclosed by the Company, and such amounts will be included in the balance of unutilized proceeds.

Working capital and financial resources

Cash flow analysis

As at 30 June 2026, net cash inflow generated from operating activities was approximately RMB34.32 million, which was mainly attributable to changes in the timing of bill settlement and a decrease in operating cash collections; the net cash inflow generated from investment activities was approximately RMB45.09 million, which was mainly due to the adjustment of wealth management product allocation and optimization of the investment fund structure; the net cash outflow generated from financing activities was approximately RMB106.95 million, which was mainly due to the payment of cash dividends during the current period, resulting in an outflow of dividend funds; and the cash and cash equivalents decreased by approximately RMB28.08 million as compared to the end of last year.

Capital expenditure

The Company's capital expenditure was mainly used in the expansion of new production base and the acquisition of production facilities. During the reporting period, the Company did not incur any capital expenditure.

Contingent liabilities or guarantees

As of 30 June 2026, the Company did not have any significant contingent liabilities or guarantees.

OTHER DISCLOSURES

Significant Investments

Pursuant to paragraph 32(4A) of Appendix D2 to the Listing Rules, the Company would like to provide information in respect of its significant investments with a value of 5% or more of the Group's total assets as at 30 June 2026 and its financial assets at fair value through profit or loss, which included certain structured deposit products (the “**Structured Deposit Products**”) subscribed by the Group from Bank of Beijing.

The subscription of the structured deposit products by the Company is a reasonable and effective use of a certain portion of its temporarily idle capitals out of proceeds from the public offering of A Shares and its internal resources, which is conducive to enhancing the Group's overall capital return, and in line with the Company's core objective of safeguarding its capital while ensuring liquidity.

All redeemed as of 30 June 2026:

Trustee	Type of entrusted wealth management	Amount of entrusted wealth management (RMB0'000)	Commencement date of entrusted wealth management	Expiry date of entrusted wealth management	Capital Source	Annualised Yield	Actual Gains or (losses) (RMB0'000)	Actual recovery
Bank of Beijing — Daxing Sub-branch	Structured deposits	29,000.00	13 November 2025	18 May 2026	Idle capital	1.2 or 1.9%	280.78	Full Redemption
Bank of Beijing — Fang Zhuang Sub-branch	Structured deposits	29,000.00	13 November 2025	18 May 2026	Internal funds	1.2 or 1.9%	280.78	Full Redemption
Bank of Beijing — Fang Zhuang Sub-branch	Structured deposits	21,000.00	13 November 2025	18 May 2026	Idle capital	1.2 or 1.9%	203.33	Full Redemption

Unredeemed as of 30 June 2026:

Trustee	Name of product	Type of entrusted wealth management	Amount of entrusted wealth management (RMB0'000)	Fair value as at 30 June 2026 (RMB0'000)	Size of fair value relative to the Group's total assets	Commencement date of entrusted wealth management	Expiry date of entrusted wealth management	Capital Source	Money Flow	Annualised Yield	Actual recovery
China Construction Bank — Daxing Sub-branch	CCBC Entity-targeted RMB Customised Structured Deposit	Structured deposits	18,500.00	18,500.43	5.15%	29 June 2026	30 December 2026	Idle capital	Banking	0.85% to 1.75%	Undue, not redeemed at the end of the reporting period
Shanghai Pudong Development Bank, Beijing Branch	Li Duo Duo Company Stable Profit 26JG8366 (Bullish Three-tier) RMB-denominated Structured Deposit Product* (利多多公司 穩利26JG8366期 (三層看漲) 人民幣 對公結構性存款)	Structured deposits	44,000.00	44,005.73	12.25%	25 June 2026	25 December 2026	Internal funds	Banking	0.95% or 1.65% or 1.85%	Undue, not redeemed at the end of the reporting period
Bank of Beijing — Daxing Sub-branch	EUR/USD Fixed-day Observation Interval Structured Deposits	Structured deposits	10,000.00	10,000.27	2.78%	29 June 2026	28 December 2026	Idle capital	Banking	1.00% or 1.72%	Undue, not redeemed at the end of the reporting period
			<u>72,500.00</u>	<u>72,506.43</u>	<u>20.19%</u>						

Note 1: Bank of Beijing is a licensed bank in the PRC and a joint stock company established under the laws of the PRC, which provides corporate and personal banking business, treasury business, finance leasing, asset management and other financial services in the PRC. Its shares are listed on the Shanghai Stock Exchange (stock code: 601169). Bank of Beijing (Fangzhuang Branch) and Bank of Beijing (Daxing Branch) are branches of Bank of Beijing. To the best of the directors' knowledge, information and belief having made all reasonable enquiry, Bank of Beijing and its ultimate beneficial owner(s) are third parties independent of the Company and its connected persons.

Note 2: China Construction Bank is a joint stock commercial bank in the PRC which provides services such as accepting deposits, making loans and offering basic investment products. Headquartered in Beijing, it was listed on the Stock Exchange in October 2005 (stock code: 939) and the Shanghai Stock Exchange in September 2007 (stock code: 601939). China Construction Bank (Daxing Branch) is a branch of China Construction Bank. To the best of the directors' knowledge, information and belief having made all reasonable enquiry, China Construction Bank and its ultimate beneficial owner(s) are third parties independent of the Company and its connected persons.

Note 3: Shanghai Pudong Development Bank is a licensed bank in the PRC and a joint stock company established under the laws of the PRC, which provides corporate and personal banking business, treasury business, finance leasing, asset management and other financial services in the PRC. Its shares are listed on the Shanghai Stock Exchange (stock code: 600000). Shanghai Pudong Development Bank (Beijing Branch) is a branch of Shanghai Pudong Development Bank. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, Shanghai Pudong Development Bank and its ultimate beneficial owner(s) are third parties independent of the Company and its connected persons.

SUBSEQUENT EVENTS

From the end of the reporting period to the date of this announcement, the Group did not have any other significant events.

FUTURE PROSPECTS

Looking forward, various favourable factors such as aging population, continuous increase in per capita income and enlarging scope of the medical insurance coverage will continue to sustain the rapid development of the healthcare market in the PRC, especially the orthopedic medical device industry. The Company believes that the demand of our products will continue to increase along with the growth of the PRC joint prosthesis market. In the long run, the Company aims to become a leading enterprise in the market with a full range of orthopedic medical device products and to become one of the internationally renowned orthopedic medical device manufacturers. The Company implements the following strategies:

Diversify our product series

The Company will continue to optimize and modify its existing products, and keep abreast of the technology development of the joint prosthesis sector and invest more resources in the research and development of new products. The Company will strengthen production, operation and internal management, enhance its product innovation capacity and reinforce marketing promotion. The Company will develop new markets on the basis of consolidating existing markets consistently and strive to improve the market share of the related products. The Company will develop more products catering for patients' needs through the application of new materials and the improvement of production processes, in order to build a more comprehensive product series and to achieve product diversification. The Company has continued to lead the high-value orthopedic implant products in China and carried out innovative research and development of joints as main business to provide a more various and tailor-made product series for the Chinese people and to stay ahead in the domestic joint implants market. In addition, the Company has expanded and perfected the product line in the field of orthopedic, for instance, the orthopedic robots, spine, trauma and sports medicine products, and boosted the strategic layout in dentistry, and PRP products. Furthermore, the Company has also closely focused on the development of related new technologies, such as new bio-materials and drug-device combinations and other products. While maintaining its leading position in the domestic market, the Company has also improved its international business team building and increased investment in marketing promotion with a view to developing the international market.

The development of domestic orthopedic medical devices is moving towards customization, minimally invasiveness and intelligence approaches. With the development of China's national economy, there will be more demand domestically for customized products. The customized joint prosthesis products of the Company primarily include two categories: traditional customized joint prosthesis products and assembled customized joint prosthesis products. Traditional customized joint prosthesis products are designed and manufactured in accordance with the skeletal structure data of specific patients based on the needs of the patients. Assembled customized joint prosthesis products are designed and manufactured based on the statistical analysis of numbers of patients' clinical data and clinically assembled from off-the-shelf components of various specifications and sizes. Compared to traditional customized joint

prosthesis products, assembled customized joint prosthesis can be manufactured and assembled in a shorter period of time to meet the needs of different patients, thus minimizing the delays in medical procedures.

The Company possesses a full range of customized joint technologies, including 3D printed osteotomy guide boards for the hip, knee, shoulder, elbow, spine, small joints of the extremities and maxillofacial positions, which are intended to be used for the position, guide and protection during osteotomies at the joint site. The 3D printed osteotomy guide boards can be highly compatible with the anatomical shape of the patients' bone tissue with its customized design and additive manufacturing and position and guide accurately during osteotomies, which can greatly reduce the time of osteotomy in joint surgery, minimize surgical errors and boost the surgery success rate and patient satisfaction to a significant extent. The Company believes that advanced, customized and individualized joint prosthesis products can generate higher profit margins. In recent years, the relevant regulations issued by the NMPA are also more conducive to the development of customized prostheses. The Company will take this opportunity to promote the rapid development of patents for customized and individualized products.

Strengthen the Company's innovation ability and increase the research and development resources

In the future, the Company shall continue its focus on the research and development of standard joint prosthesis products, advanced customized and individualized joint prosthesis products, orthopedic robots, spinal products, trauma, sports medicine products, PRP products and dental products. The Company plans to establish a product research and development center at Daxing New Production Base, which is expected to consist of research and development centers on joint product, spinal product and orthopedic trauma product. Meanwhile, the Company will recruit more research and development talents to join its research and development team and continue to increase its expenditure on the verification of the research and development projects. In addition, under the support of the post-doctoral scientific research workstation and National Enterprise Technology Centre* (國家企業技術中心), the Company will focus on cultivating the research and development standards and innovation capabilities of research and development personnel, while continuously optimizing the allocation of research and development resources and iterating on corporate innovation mechanism. The Company can also make good use of the National Enterprise Technology Centre* (國家企業技術中心) and post-doctoral scientific research workstation to strengthen cooperation with renowned medical institutions in the PRC in order to enhance its professional knowledge, technology and competitiveness.

Expand brand influence

To further strengthen its brand, the Company will continue to implement strict supervision on product quality. At the same time, the Company will actively organize and participate in seminars for market practitioners including distributors and representatives from hospitals on orthopedic medical devices with well-known experts and professors in the industry from both the PRC and overseas to promote its products during such seminars. The Company will also strengthen the cooperation with different academic institutes and hospitals and organize academic seminars at different levels and in various aspects.

Talent development and incentives

The Company will continue to adhere to its existing talent development policy while establishing a new training system for talent development and attracting high-quality talents with a competitive remuneration system. On the other hand, the Company has established an effective incentive and appraisal system to motivate the work initiative and enthusiasm of employees.

EMPLOYEE

As at 30 June 2026, the Company had approximately a total of 969 employees, which included management, production, quality and monitoring staff, research and development personnel, sales and marketing staff and general and administration staff. As of 30 June 2026, the total salaries and related costs paid to our employees were approximately RMB102.73 million. The Company enters into individual employment contracts with employees to cover matters such as salaries, bonus, employee benefits, contract term, duties, location of workplace, working hours, resignation policies, labour protection, confidentiality, non-competition and grounds for termination, etc.

PURCHASE, REDEMPTION OR SALE OF LISTED SECURITIES OF THE COMPANY

During the six months ended 30 June 2026, neither the Company nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities.

As at 30 June 2016, the Company held 1,376,851 treasury shares, all of which were A Shares, and the intended use of which was for the implementation of employee stock ownership plans or equity incentive schemes.

INTERIM DIVIDEND

The net profit attributable to owners of the parent company for the half-year of 2026 amounted to RMB119,957,018.06. Taking into account the reasonable returns for investors and the long-term development of the Company, and under the premise of guaranteeing the Company's normal operation and business development, the Board has resolved to make a profit distribution for the half-year of 2026 on the basis of the total share capital registered on the date of the implementation of the rights registration for the distribution, less the amount of the shares held by the repurchase account. The proposed profit distribution is set out below:

The Company proposes to distribute a cash dividend of RMB1.3 (before tax) for every 10 shares to all shareholders. As at 30 June 2026, the total share capital of the Company was 383,568,500 shares, and after deducting the number of shares held by the A-share repurchase account of 1,376,851 shares, the actual number of shares participating in the profit distribution was 382,191,649 shares, and based on this calculation, a total of RMB49,684,914.37 (before tax) was proposed to be paid out as cash dividend. The amount of cash dividend of the Company in the first half of 2026 accounts for 41.42% of the net profit attributable to shareholders of the listed company in the consolidated statement. The Company will not carry out any capitalization of capital reserve or distribute bonus shares.

If the total share capital of the Company changes as a result of conversion of convertible bonds, share repurchase, share buyback and cancellation of share repurchase under share incentive scheme, share buyback and cancellation of share repurchase under major asset reorganization during the period from the date of disclosure of this announcement to the date of registration of the rights to implementation of the profit distribution, the Company intends to maintain the amount of the cash dividend per share as it is and adjust the total amount of the distribution accordingly, and will make a separate announcement of the specific adjustments.

The proposed profit distribution has been considered and approved at the second meeting of the sixth session of the Board of the Company and is subject to the approval of the 2026 extraordinary general meeting of the Company for implementation. The dates of closure of register of members of the Company for the purpose of determining the identity of shareholders entitled to attend the 2026 extraordinary general meeting and to receive the proposed interim dividend and the payment date of the said interim dividend will be announced later.

CORPORATE GOVERNANCE

The Board has been committed to maintaining a high standard of corporate governance. The Board believes that, the high standard of corporate governance is essential in providing a framework for the Group to safeguard shareholder interest, enhance enterprise value, formulate its business strategy and policy, and enhance the transparency and accountability. The Company has adopted the principles and code provisions of the Corporate Governance Code set out in Appendix C1 to the Listing Rules. The Board considers that during the reporting period, the Company has complied with all the code provisions contained in the Corporate Governance Code.

COMPLIANCE WITH MODEL CODE

The Company has adopted the “Model Code for Securities Transactions by Directors of Listed Issuers” contained in Appendix C3 to the Listing Rules (the “**Model Code**”) as its code of conduct for directors’ securities transactions. Having made specific enquiry with the directors, all of the directors confirmed that they have complied with the required standard as set out in the Model Code throughout the six months ended 30 June 2026.

REVIEW OF INTERIM RESULTS BY AUDIT COMMITTEE

WUYIGE Certified Public Accountants LLP has reviewed these financial statements.

The Audit Committee of the Board has reviewed the Company’s consolidated financial statements for the six months ended 30 June 2026, including the accounting principles and practices applied.

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND THE INTERIM REPORT

This results announcement will be published on the Company's website (www.clzd.com) and the HKExnews website of the Stock Exchange (www.hkexnews.hk).

The Company's 2026 Interim Report containing all information required under the Listing Rules will be published on the Company's website and the HKExnews website of the Stock Exchange in due course.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Wenling
Chairman

Beijing, the PRC, 28 August 2026

As at the date of this announcement, the executive Directors of the Company are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Ms. Xu Hong, Mr. Kwan King Nam and Mr. Zheng Zhong Liang.

* For identification purposes only